Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial  by Kabra, S.K. et al.
Journal of Cystic Fibrosis 9 (2010) 17–23
www.elsevier.com/locate/jcfOriginal Article
Long-term daily high and low doses of azithromycin in children with cystic
fibrosis: A randomized controlled trial
S.K. Kabra ⁎, R. Pawaiya, Rakesh Lodha, Arti Kapil, Madhulika Kabra,
A. Satya Vani, G. Agarwal, S.S. Shastri
Department of Pediatrics and Microbiology, All India Institute of Medical Sciences, New Delhi 110029, India
Received 3 April 2009; received in revised form 30 August 2009; accepted 10 September 2009
Available online 8 October 2009Abstract
Background: Long-term administration of azithromycin (AZM) in children with cystic fibrosis (CF) has improved outcomes. However, the doses
and schedule of administration are not very well studied in children with CF.
Methods: A randomized controlled trial was conducted to compare the effect of two doses of azithromycin (5 mg/kg/day and 15 mg/kg/day) on
FEV1 and pulmonary exacerbations in children with cystic fibrosis. Enrolled children were randomly allocated to receive daily azithromycin
(5 mg/kg/day or 15 mg/kg/day) for 6 months. Clinical assessment and FEV1 measurement were performed monthly.
Results: 56 children (28 in high dose group and 28 in low dose group) were enrolled. 47 (24 and 23 children in low and high dose groups)
completed 12 months of follow up. There was no difference in clinical scores, FEV1, pulmonary exacerbation rates between two groups at
baseline, 6 months and at 12 months. Per protocol analysis revealed that pulmonary exacerbation increased after discontinuing AZM and there was
significantly more increase after 12 months of enrolment in children getting high dose azithromycin. There was no improvement in FEV1 in either
group at the end of treatment period. Children tolerated daily low as well as high dose AZM well for 6 months. There was no significant side effect
of azithromycin.
Conclusion: In this randomized controlled trial, we did not find differences in the effect of 2 doses (5 mg/kg/day or 15 mg/kg/day) of AZM on
change in percentage predicted FEV1, clinical scores, Pseudomonas colonization rates, pulmonary exacerbations and need for antibiotics. There
was increase in exacerbations after stopping azithromycin in both the groups. Our results also suggest that the decrease in the incidence of LRTI
persists only till 6 months after discontinuing azithromycin.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Azithromycin; Clinical scores; Cystic fibrosis; FEV11. Introduction
Cystic fibrosis (CF) is a multisystem disorder and pulmonary
involvement is most dramatic. Patients with cystic fibrosis are
characterized by recurrent respiratory infection and inflamma-
tion along with fat malabsorption and micronutrient deficiency.
Pulmonary manifestations are because of infection with Pseu-
domonas and early and relentless pulmonary inflammation [1–
3]. There is growing interest in the use of macrolides as immune
modulating drugs in cystic fibrosis. They have been shown to⁎ Corresponding author. Fax: +91 11 26588941.
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doi:10.1016/j.jcf.2009.09.001decrease sputum viscoelasticity and airway adhesion of Pseu-
domonas aeruginosa [4].
There are studies to document improved outcome in children
with CF treated with azithromycin (AZM) as compared to
placebo [5–8]. Despite the availability of this new information,
many questions remain unanswered about the use of AZM in
cystic fibrosis including the dose, the correct dose interval, its
duration of effect and the impact of long-term treatment with
AZM on disease progression and the microbiology of the lung.
Daily versus once a week administration of AZM has been
compared and shown equivalent results [9] but there are no
studies to compare different doses of AZM in children. We
conducted a study with the hypothesis that children with cystic
fibrosis treated with high dose azithromycin (15 mg/kg) onced by Elsevier B.V. All rights reserved.
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predicted FEV1 as compared to patients treated with azithro-
mycin (5 mg/kg) once daily for 6 months.
2. Methods
This randomized controlled trial was conducted in the
Pediatric Chest Clinic of All India Institute of Medical
Sciences, New Delhi India. Children with cystic fibrosis of
either sex, 5–18 years of age being followed up in the clinic
were subjects of study. Patients were diagnosed with cystic
fibrosis on the basis of characteristic signs and symptoms, plus
a positive sweat test at least twice, or two defined cystic
fibrosis gene mutations.
2.1. Inclusion criteria
Children between 5 years and 18 years diagnosed as cystic
fibrosis as defined above who were able to perform spirometry,
able to swallow suspension, willing to come for follow up, had
forced expiratory volume (FEV1) of less than 80% predicted,
clinically stable at the time of enrolment and no intravenous
antibiotics administered for at least 2 weeks prior to enrolment,
were eligible for the study.
2.2. Exclusion criteria
Children with cystic fibrosis related liver disease, or liver
function tests greater than 3 times the laboratory upper limit, who
had received macrolide antibiotics or oral steroids for more than
7 days in the month prior to enrolment, with history of allergy to
macrolides or known or suspected intolerance to sputum in-
duction, were excluded.
2.3. Methods
Parents of children who fulfilled inclusion criteria and did
not have exclusion criteria were invited to participate in the
study. A written informed consent was obtained from parents.
Children were randomized to receive 5 mg/kg/day or 15 mg/kg/
day of azithromycin by computer generated blocks of four.
Children were given azithromycin in addition to supportive care
for the first 6 months. Supportive care included: regular
physiotherapy (postural drainage), enzyme replacement, vita-
mins A, D and E supplementation (2 RDA), liberal salt intake,
inhaled bronchodilators and steroids and antibiotics whenever
detected to have pulmonary exacerbation. Children were
assessed to have pulmonary exacerbation if there was increase
frequency, severity or duration of cough with change in amount
or nature of expectoration. Children with pulmonary exacerba-
tions were hospitalized if there was breathlessness (increased
respiratory rates with chest indrawing) and/or hypoxia (oxygen
saturation b90%). They were treated with intravenous ceftaza-
dime and amikacin (or other antibiotics depending on isolation
and sensitivity of pathogens) for 2 weeks. Children with
pulmonary exacerbation but no breathlessness or hypoxia
were treated on ambulatory basis with fluoroquinolones ifcolonized with Pseudomonas or amoxy-clavulanic acid if not
colonized with Pseudomonas. Antibiotics were changed
according to culture reports. None of the study subjects during
study period received alfa dornase (DNASe) or inhaled
tobramycin.
Patients were followed up every month for a minimum of
12 months. Azithromycin suspension was dispensed with
adequate supply for 1 month on each follow up visit for the first
6 months. At every visit a history and physical examination was
performed. The patient's weight was measured to the nearest
0.1 kg, and the height in centimeter to the nearest mm using
a stadiometer. Spirometry was performed according to the
American Thoracic Society/ERS guidelines [10] and sputum
(children above 6 years of age) or cough swab (children below
6 years of age) cultures [11] was obtained. All changes in symp-
toms and treatment were recorded on the predesigned performa.
Any need for oral or intravenous antibiotics or hospitalization was
recorded.
On each visit patients were assessed on modified clinical
scores that are being used routinely in our clinic [12]. All
children were assessed on scores for general activity, physical
examination and nutritional status. Each category scored from 5
to 25, maximum scores of 75 indicating excellent clinical con-
dition. Patient were assessed to be having mild illness, moderate
illness and severe illness on basis of clinical scores of 57–75,
38–57 and b37 respectively.
Before the treatment period began blood was drawn from
each patient for ESR and liver function tests. Sputum/cough
swab was collected for microbiological analysis on each visit.
2.4. Sputum microbiology
Sputum was cultured by using standard techniques [13]. We
studied the effect of azithromycin on production of mucoidy by
P. aeruginosa. Children with at least two positive cultures for
Pseudomonas in past 12 months were considered as colonized
with Pseudomonas. Other organisms on culture with sensitivity
were recorded.
2.5. Adherence to the medications
Adherence to azithromycin was assessed by asking the par-
ents and seeing the medications that remained unused on each
visit.
2.6. Sample size
The primary study outcome was change in FEV1 % predicted
and was based on improvements in the FEV1 reported in the
open study by Jaffé et al. [14]. A sample size of 8 per group is
required to detect a difference of 10% between high and low
doses of AZM with 90% power and 5% statistical significance.
2.7. IL-8 estimation
The concentrations of IL-8 were determined by quantitative
sandwich enzyme immunoassay technique, using a IL-8 ELISA
Table 1
Baseline characteristics of patients in two groups.
Characteristics Group A (N=24)
(AZM 5 mg/kg/day)
Group B (N=23)
(AZM 15 mg/kg/day)
p
Age mean±SD (years) 9±5.1 7±4.6 0.16
Age at diagnosis
mean±SD (years)
5.4±3.6 2.7±2.4 0.004
Sex
Males 14 20 0.028
Females 10 3
Clinical features at time of enrolment
Cough
Wheeze 21 21 0.672
Breathlessness 8 11 0.32
Recurrent pneumonia 15 16 0.609
Pain chest 5 9 0.179
Hemoptysis 3 3 0.955
Pain abdomen 3 0 0.08
Large bulky stools 5 4 0.764
Oil in stools 8 6 0.587
Mean weight (SD), kg 1 3 0.276
Median height (SD), cm 13.91 (7.17) 14.39 (11.07) 0.569
FEV1 L (SD) 95.79 (25.02) 95.43 (27.01) 0.481
% predicted FEV1 1.10 (0.67) 1.09 (0.32) 0.489
51.07±23.5 65.66±14.80 0.96
Delta F 508 homozygous 2 2 1.0
Heterozygous 2 2
Othr mutations than
Delta F 508
20 19
Clinical scores
Mean (SD) 54.75 (12.08) 53.63 (11.03) 0.378
Chronic Pseudomonas
infection
10 12 0.47
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manufacturer's instructions. Standard curve of IL-8 was plotted
using different concentrations of IL-8 standard— 0, 31.2, 125,
500, and 2000 pg/mL. For estimation of IL-8 concentration in a
sputum sample, the sol phase was prepared [15]. The samples
were stored at −70 °C till they were processed. The O.D. was
measured at 450 nm with a microplate reader (Thermo Electron
Corporation, Multiskan EX).
2.8. Statistical tests
Baseline characteristics were compared between the two
groups. Differences in FEV1 between the 2 groups were as-
sessed by the Student's T test and differences in secondary
outcomes by the chi square test. STATA (College station,
Texas, USA) was used for statistical analysis.
The study was approved by the Ethics committee of our
institution.
3. Results
The study was conducted from August 2005 to Dec 2007.
A total of 56 (28 patients in each group) children with cystic
fibrosis were enrolled. Nine patients (4 in low dose group
and 5 in high dose group) did not complete follow up of
12 months. For final analysis, 24 children received azithro-
mycin 5 mg/kg/day (group A) and 23 received 15 mg/kg/day
(group B) for 6 months. Some children (8 in low dose group
and 9 in high dose group) were followed up to 18 months
(Fig. 1).
3.1. Baseline characteristics
The baseline data of two groups are given in Table 1. They
were similar for age, age of onset, clinical features, weight,
height, FEV1, clinical scores, colonization with Pseudomonas
and common mutations (Delta F 508). There were more boys in
the group receiving high dose AZM (15 mg/kg/day).Fig. 1. Trial3.2. Change in percentage predicted FEV1 and other
spirometric parameters
The average percentage predicted FEV1 did not differ in two
groups at baseline, 3 months, 6 months and 12 months between
two groups (Table 2). At 18 months the numbers of children in
group A and B were 8 and 9 respectively. The percentage
predicted FEV1 was maintained till 9 months after that thereprofile.
Table 3
Pulmonary exacerbation rates in two groups.
Time after
enrolment
Group A
(AZM 5 mg/kg/day)
Group B
(AZM 15 mg/kg/day)
p
0–6 months 0.1±0.301 per
child/month
0.05±0.229 per
child/month
0.526
6–12 months 0.2±0.405 per
child/month
0.17±0.429 per
child/month
0.812
12–18 months 0.24±0.426 per
child/month
0.34±0.477 per
child/month
0.425
p comparing
exacerbations
between the first
6 months with
the last 6 months:
0.321
p comparing
exacerbations
between the first
6 months with
the last 6 months:
0.0275
Table 4
Organisms identified in pulmonary exacerbations in two groups.
Microorganisms Group A Group B p
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values of percentage predicted FEV1 at time of enrolment at
6 months, 9 months and 12 months were 51, 47, 51 and 52%
respectively suggesting no improvement in FEV1. However,
there was a trend showing decline at 12 and 18 months com-
pared to baseline. In group B the FEV1 values at enrolment,
6 months, 9 months and 12 months were 65, 65, 53 and 57%
respectively. There was significant decline at 9, 12 and
18 months. A subgroup analysis was done for 22 children
who were chronically infected with Pseudomonas (10 and 12 in
low and high dose groups). Their baseline characteristics were
comparable (data not shown). Their FEV1 did not differ and the
values at baseline were 56.8±20.6 L and 60.6±20.8 L, at
6 months were 57.2 ± 22.00 L and 62.6 ± 25.9 L and at
12 months were 50.6±20.4 L and 55.5±14.9 L.
The other spirometric parameters (FVC, FEF25–75 and
PEFR) were comparable in two groups at baseline, 6 months,
and 12 months (not shown).
3.3. Pulmonary exacerbations and antibiotic use
The numbers of pulmonary exacerbations in two groups
were comparable. The rates per child per month during treat-
ment period (first 6 months) were 0.1 and 0.05, between 7 and
12 months 0.2 and 0.17 per child per month and between 13 and
18 months 0.233 and 0.339 in low and high dose groups
respectively (pN0.5). However, the exacerbations increased
significantly during the last 6 months of follow up in high dose
group. In low dose group it increased from 0.1 to 0.233 per child
per month and in high dose group the rate of pulmonary
exacerbations increased from 0.05 to 0.339 per child per month
(pb0.05). (Table 3).
3.4. Culture of deep throat swabs for Pseudomonas and its
sensitivity pattern
The number of children positive for Pseudomonas on deep
throat swabs in the last 12 months was similar in two groups atTable 2
Changes in percentage predicted FEV1 in relation to time.
Time Group A
Mean (SD)
(AZM 5 mg/kg/day)
Group B
Mean (SD)
(AZM 15 mg/kg/day)
p
Baseline 51.07±23.5 65.66±14.80 0.9603
3 months 55.62±23.68 62.62±19.22 0.7366
6 months 47.12±20.00 65.67±29.97 0.9233
9 months 51.5±28.62 53±16.99 0.5344
12 months 52.66±15.04 57.5±12.09 0.6923
18 months 47.5±19.39 45.33±14.57 0.4354
p comparing p comparing
Baseline with
6months: 0.2712
Baseline with
6months: 0.5006
Baseline with
9months: 0.5221
Baseline with
9months: 0.0042
Baseline with
12months: 0.6081
Baseline with
12months: 0.0210
Baseline with
18months: 0.2885
Baseline with
18months: 0.000different times. A total of 22 (10 in group A, 12 in group B)
were positive for Pseudomonas in the last 12 months. Two each
in two groups were assessed to be producing mucoidy colony of
P. aeruginosa. All the isolates were resistant to azithromycin as
the minimum inhibitory concentration was N8 µg/dL.
A total of 113 pulmonary exacerbations (48 in low dose and 65
in high dose group) were recorded during study period and follow
up. Organisms identified on sputum/cough swabs were P. aerugi-
nosa, Staphylococcus aureus, Streptococcus hemolyticus, Strepto-
coccus pneumoniae and Candida albicans (Table 4). The
distribution was similar in two groups.
S. aureus were isolated from 10 samples (4 in low dose and 6
in high dose group) from6 patients. All weremethicillin sensitive.(total exacerbations 62)
(AZM 5 mg/kg/day)
Episodes/patients
(total exacerbations 68)
(AZM 15 mg/kg/day)
Episodes/patients
Pseudomonas aeruginosa
0–6 months 9/7 10/9
7–12 months 9/6 13/8
13–18 months 4/4 7/3
Total 22/12 30/10 0.76
Staphylococcus aureus
0–6 months 3/2 5/3
7–12 months 1/1 1/1
13–18 months 0 0
Total 4/3 6/3
0.60
Streptococcus
hemolyticus
2/1 0 –
Streptococcus
pneumoniae
0 1/1 –
Candida albicans 1/1 1/1 –
No organisms
isolated
33 30 0.43
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The average composite clinical scores at baseline at different
time periods were comparable in two groups (Fig. 2). The
average clinical scores in group A at baseline, 6 months, and
12 months were 54, 56 and 47 respectively. A significant trend
of improvement till 6 months and subsequent decline at
12 months was observed (pb0.05). The average clinical scores
at baseline, 6 months and 12 months in group B were 53, 55 and
56 respectively. There was a trend of decline in clinical scores in
both the groups at 18 months.
3.6. Changes in the weight of children at different
time intervals
The average weights in group A at baseline, 6 months and
12 months were comparable in two groups. The average
weights in group A at baseline, 6 months and 12 months were
17, 21 and 17 kg respectively. In group B the average weights at
baseline, 6 months and 12 months were 16, 19, and 19 re-
spectively. There was a trend to suggest that average weight
increased in the first 6 months after that there was a decline in
weight. In group B, there was weight gain for 6 months and
after that it was maintained (Table 5).
3.7. IL-8 concentration in sputum
IL-8 levels were performed at baseline and at the end of
6 months in 7 and 6 patients in low and high doses ofAZMgroups
respectively. The levels were more than 2000 pg/mL in all.
3.8. Adherence to the study drug
All children who completed the follow up received N80% of
the doses of azithromycin.
4. Discussion
In this randomized controlled trial we did not find difference
in the effect of doses of 5 mg/kg/day or 15 mg/kg/day of AZM
on change in percentage predicted FEV1, clinical scores,Fig. 2. Clinical scores in two groups with time.Pseudomonas colonization rates, pulmonary exacerbations
and need for antibiotics. There was an increase in exacerbations
after stopping azithromycin in both the groups. Though there
was no significant improvement in FEV1 during treatment with
azithromycin but there was a significant decline after 3months
of stopping azithromycin.
Information on the doses and schedule of AZM treatment in
childrenwithCF is scanty. In an earlier report comparing high and
low doses of azithromycin (250 mg daily versus twice weekly) in
CF patients colonized with Pseudomonas it was reported that the
sputum concentration of AZM was less in low dose as compared
to high dose {9.5 µg/mL (0.6 to 79.3 µg/mL, interquartiles 1.4 to
33.4 µg/mL} and 0.5 µg/mL {range less than 0.1 (below de-
tection level to 5.2 µg/mL, interquartiles 0.2 to 1.4 µg/mL},
suggesting that there may be some effect of different doses on
the clinical outcome [16]. The regular doses recommended for
azithromycin is 10 mg/kg/day for infections. We decided to
compare 5 and 15 mg/kg/day.
There are few studies comparing different doses of azithro-
mycin for comparison with results of our studies. McCormack
et al., in their study on 208 patients treated either with 250 mg
daily (n=103) or 1200 mg weekly (n=105) of azithromycin for
6 months, demonstrated equivalence of the two groups with
respect to improvements in lung function (forced expiratory
volume in one second and forced vital capacity), C-reactive
protein, days spent in hospital, admission rates and nutrition. In
patients aged b18 years, the daily group had significantly better
improvements in z-scores for height and weight after 6 months
[9]. The dose of daily AZM was 1850 mg per week as compared
to 1200 mg in those who received weekly AZM.
Saiman et al. evaluated efficacy of AZM in low dose [250 mg
(weight b40 kg) or 500 mg (weight ≥40 kg) of oral azithro-
mycin 3 days a week] for 168 days and demonstrated a
significant improvement in FEV1 at day 168 compared with
placebo. They also demonstrated that azithromycin group had
less risk of experiencing an exacerbation than participants in the
placebo group [7], suggesting efficacy of low dose AZT.
In our study, we did not find significant improvement in
spirometric parameters from baseline to end of treatment (at
6 months). The reported improvements in FEV1 and other
responses have been variable. Wolter et al., in their study com-
paring placebo and azithromycin, documented that in AZMgroup
FEV1 was maintained but in placebo group there was a decline in
the parameters [5]. We did not have a placebo group in our study
[5]. Equi et al. in their placebo-controlled crossover trial on 41 CF
patients demonstrated that FEV1 improved by more than 13% in
13 of 41 patients and five of 41 deteriorated by more than 13%
with no change in FVC and mid-expiratory flow suggesting a
variable improvement in FEV1 [6].
Southern et al. in their meta-analysis at the two-month time
point demonstrated a significant benefit with respect to
percentage change in FVC from azithromycin, but no difference
with respect to percentage change of FEV1 [17]. In the study by
Clement et al., though other parameters improved at the end of
12 months of treatment with AZT, the relative change in FEV1
at month 12 did not differ significantly between the two groups
[8]. Steinkamp et al. in a randomized double-blind, placebo-
Table 5
Average weight of patients at different time intervals.
Time of follow up Group A (AZM 5 mg/kg/day) Group B (AZM 15 mg/kg/day) p
Baseline 17.48±13.33 (11.97–22.98) 16.43±9.54 (12.30–20.56) 0.75
3 months 17±17.42 (7.713–26.28) 18.3±11.57 (12.88–23.71) 0.53
6 months 21.09±18.80 (8.45–33.72) 19.09±10.94(11.73–26.44) 0.76
12 months 17.14±15.62 (8.11–26.16) 19.90±8.64 (14.10–25.71) 0.60
18 months 18.57±10.87 (8.51–28.62) 23.5±13.59 (12.13–34.86) 0.45
p values comparing p values comparing
Baseline with 6 month: 0.4 Baseline with 6 month: 0.37
Baseline with 12 months: 0.93 Baseline with 12 months: 0.19
Baseline with 18 months: 0.83 Baseline with 18 months: 0.12
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inflammatory reactions and improved quality of life. A decline
of pulmonary function after cessation of intravenous antibiotics
could not be prevented [18].
Heterogeneity in the treatment effect has been documented and
depends on severity of disease, concomitant medications and
genotype, however all patient may show some improvement in
clinical outcomes [19]. In our study, we included all children
irrespective of colonization with Pseudomonas, nutritional status
and baseline FEV1. The patients were assessed to be having
moderately severe disease as indicated by average clinical scores
of 54 and 53 in the two groups receiving AZM 5 mg/kg/day or
15 mg/kg/day respectively. Their percentage predicted FEV1 was
also 51% and 65% respectively. It is suggested that azithromycin
may be altering P. aeruginosa biofilm formation and providing
clinical benefit in cystic fibrosis patients [20]. In our study only 22
(46%) patients had chronic Pseudomonas infection. None of
them were getting DNAse or inhaled tobramycin. These factors
may explain lack of improvement in FEV1. However, the
randomization would have distributed the cases in both the limbs
equally. It has been observed that azithromycin prevents decline
in the FEV1 as compared to placebo [5]. Since we did not have
placebo group and data on the normal decline in FEV1 in our
study population, we may not be able to demonstrate any
difference in the decline in FEV1 as well as prevention of decline
in FEV1 in our study.
We documented high levels of IL-8 at enrolment and at com-
pletion of 6 months. There was no reduction in levels of IL-8 in
both the groups at completion of 6 months of treatment. An anti-
inflammatory mechanism of action has been suggested for
macrolide antibiotics [21]. But earlier studies also have not shown
statistically significant reductions in IL-8 [7] with AZM.
4.1. Limitations of study
Our study has certain limitations. The group of patients we
enrolled included children with and those without colonization
with Pseudomonas. Most studies demonstrated improvement
in patients with colonization with Pseudomonas. This may be
responsible for no significant improvement in FEV1 frombaseline
to end of treatment. Other limitations of our studywerewe did not
perform drug levels in sputum or blood nor did we estimate
inflammatory markers (CRP, etc.) to document decrease in
inflammation; these would have strengthened the results of ourstudy. The reverse power calculation revealed a power of study as
70%, a larger study with adequate sample size with uniform
characteristics of study subjects may be needed to confirm the
results.
4.2. Summary and conclusions
The two doses of AZM (5 mg/kg/day or 15 mg/kg/day) did
not differ in their effects on lung function, exacerbation rates
and microbiology. The number of exacerbations increased sig-
nificantly after 12 months of enrolment.
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